Skip to main navigation
Skip to main content
Schrödinger

    Client Secondary Menu

  • Download
  • Contact
  • Support

    About

  • About
      • Team
      • Our Story
      • Culture
      • Diversity & Inclusion
      • Platform

      • Platform
          • Overview
          • Drug Discovery
          • Materials Science
          • All Products A-Z
          • Publications
          • Pipeline

          • Pipeline
          • User Events

          • User Events
          • Careers

          • Careers
          • Investor Relations (Sub Menu)

          • Investor Relations
              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

                Investor Relations (Sub Menu)

              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

              Press Release

              News & Events ( third-level-submenu)

              • Press Releases
              • Event Calendar

              Schrödinger to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

              February 18, 2021
              PDF Version

              NEW YORK--(BUSINESS WIRE)--Feb. 18, 2021-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, March 4, 2021, at 8:30 a.m. ET to discuss fourth quarter and year-end 2020 financial results and provide a general business update.

              The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 9686253. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.

              About Schrödinger
              Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

              Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

              View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005045/en/

              Jaren Madden
              Schrödinger, Inc.
              jaren.madden@schrodinger.com
              617-286-6264

              Stephanie Simon (media)
              Ten Bridge Communications
              stephanie@tenbridgecommunications.com
              617-581-9333

              Source: Schrödinger

              Investor Tools

              • Email Alerts
              • Email Alerts
              • Investor Contact
              • Investor Contact
              • Print Page
              • Print Page
              • Email Page
              • Email Page

              Social Menu

              Twitter Youtube} Google Linkedin

              Copyright © 2021 Schrödinger, Inc.

                Legal Menu

              • Citations
              • Privacy Policies
              • Terms of Use
              • FCOI Policy
              • EULA
              Back To Top